Drug discovery used to take a decade and cost a billion dollars, with a 90% failure rate. AI is compressing that timeline to months. Genetics is unlocking targets that were previously unreachable. And seven billion aging humans are creating demand that will not slow down. The pharmaceutical industry is being remade — and the next trillion-dollar companies are already visible.
Medicine has always been slow. The biology is complex, the regulation is rigorous, and the failure rate is humbling. Nine out of every ten drugs that enter clinical trials never reach patients. The average time from molecule to market has historically been twelve to fifteen years. The average cost, including failures, exceeds a billion dollars per approved drug.
Three things are changing that simultaneously — and the convergence is not incremental. It is structural.
Machine learning is identifying drug candidates in weeks that previously took years. Protein folding is solved. Antibody design success rates are doubling. Clinical trial cohorts are being identified in months not years. The 90% failure rate is beginning to fall.
CRISPR, mRNA, gene therapy, RNA therapeutics, antibody-drug conjugates — a new generation of modalities is reaching previously undruggable targets. Diseases that were managed but never cured are becoming curable. The addressable market is expanding faster than at any point in history.
700 million people over 65 by 2030. The diseases of aging — neurodegeneration, oncology, metabolic disease, cardiovascular — are the diseases with the largest unmet need and the greatest willingness to pay. This is not a cycle. It is a structural demand shift that runs for thirty years.
The $1Q thesis identifies Longer Lifespans as one of its 16 compounding forces. Every year added to the average human life is a year of economic participation, consumption, and contribution. Pharmaceutical innovation does not just save lives. It expands the productive capacity of the global economy.
"Nine out of ten drugs fail. AI is beginning to change that ratio. When it does — the economic consequences compound through every sector of the global economy."
Lilly is proof of concept. GLP-1 dominance — Mounjaro and Zepbound — proved that a single molecule addressing obesity, heart failure, and sleep apnea simultaneously can generate trillion-dollar value. The question is not whether Lilly stays above $1T. It is how far the GLP-1 franchise runs, and whether its neurodegenerative pipeline becomes the second act. AI-optimised manufacturing is already scaling production faster than any prior drug in history.
J&J's medtech-pharma hybrid is underestimated. The Kenvue spin-off removed the consumer health distraction. What remains is a high-margin pharmaceutical and surgical robotics business. Ottava — their AI-powered surgical robotic system — generates recurring revenue from procedures, not one-time device sales. CAR-T therapy Carvykti is reshaping multiple myeloma. J&J is a fortress with genuine upside that its stability obscures.
Everyone expected AbbVie to collapse when Humira's patents expired. It did not. Skyrizi and Rinvoq are growing faster than Humira ever did. The transition is essentially complete. Now the question is what comes next — and the answer is gene therapy. RGX-314 for wet AMD is in pivotal trials. AI-driven mRNA research with Anima Biotech targets oncology at the molecular level. AbbVie is rebuilding a moat that most analysts still do not fully credit.
Roche's structural advantage is unique — it controls both the diagnostic and the therapeutic. When Roche identifies an Alzheimer's biomarker, it also makes the drug targeting it. No other company has this vertical integration. Trontinemab is in late-stage Alzheimer's trials. AI-powered digital pathology is becoming the industry standard for companion diagnostics. The combination of data and treatment in one system is the highest-margin model in medicine.
Keytruda is the best-selling drug in the world. It is also a patent cliff in motion — losing exclusivity from 2028. Merck knows this. The AI-driven discovery partnership with Absci is generating novel biologics designed to extend immuno-oncology beyond Keytruda's specific mechanism. An oral PCSK9 inhibitor for cholesterol and a next-generation pneumococcal vaccine broaden the revenue base. The pipeline question is real but the management team is not ignoring it.
The Alexion acquisition gave AstraZeneca a rare disease franchise at precisely the right moment. Rare diseases command premium pricing, have limited competition, and benefit disproportionately from genetic medicine advances. Enhertu — an antibody-drug conjugate for breast cancer — is redefining what targeted oncology can achieve. The BenevolentAI collaboration is identifying new targets for lupus and pulmonary fibrosis that conventional discovery would miss.
Novartis shed everything that was not innovative medicine and concentrated on nuclear medicine and RNA therapeutics. Pluvicto — targeted radioligand therapy for prostate cancer — is a genuinely new treatment modality. Zolgensma for spinal muscular atrophy is the most expensive drug ever approved and still growing. The Microsoft AI partnership for patient stratification is reducing the trial periods required to identify who benefits from each therapy.
Pfizer may be the most undervalued name in Western pharma. The COVID revenue cliff created a valuation reset that obscures a genuine pipeline. The licensing of Chai Discovery's Chai-3 generative AI model — which doubles antibody design success rates — gives Pfizer proprietary access to previously undruggable targets. Weight-loss candidate MET-097i shows better tolerability than competitors. The market is pricing in continued decline. The pipeline does not support that thesis.
GSK is the most systematically undervalued major pharmaceutical company. The pivot to genetic-targeted drug discovery — partnering with Wave Life Sciences for frontotemporal dementia and non-small cell lung cancer — represents a structural change in how GSK finds drugs. Computational biology reducing the 90% historical failure rate is not a marginal improvement. It is a category shift. The market has not yet priced this transition. That gap will close.
India built the world's generics industry. It supplies 20% of global generic medicines by volume. That manufacturing base — the quality systems, the chemistry expertise, the regulatory relationships — is now the foundation for something more ambitious. The transition from imitation to innovation is not complete. But it is happening, company by company, pipeline by pipeline.
India's largest pharmaceutical company and the dominant force in dermatology, ophthalmology, and specialty oncology. Sun's US presence is substantial — complex generics and biosimilars that require the manufacturing expertise India has spent three decades building. The R&D investment is accelerating. Sun is the company most likely to make India's first major original drug discovery announcement in the next decade.
Divi's makes active pharmaceutical ingredients — the molecules inside medicines. As Western pharma companies diversify supply chains away from China, Divi's is the primary beneficiary. Their process chemistry capabilities are world-class. They do not need to discover drugs. They need to make the molecules that others discover, at the quality and scale that no one else can match. That is a durable, high-margin position.
Cipla's history is inseparable from access medicine — they made HIV antiretrovirals available to Africa at one dollar a day when Western pharma would not. That moral clarity is also a business model. Cipla's inhalation technology for respiratory disease is genuinely differentiated. Their US biosimilars pipeline is accelerating. And AI-driven R&D is compressing the time from molecule to filing.
Dr. Reddy's is the most aggressive investor in digital health and AI-powered discovery among Indian pharma. Their biosimilars pipeline in oncology and immunology is advancing. But the most interesting story is their bet on personalised medicine — using AI to identify which patients respond to which therapies. That capability, if proven, is worth more than any single drug in their pipeline.
Zydus made the world's first DNA vaccine — for COVID — before mRNA technology dominated the conversation. That innovation capability is being applied to gene therapy. Early AI adoption for target identification and clinical trial design is compressing their pipeline timelines. Zydus is the most technically ambitious of the Indian pharma companies and the one most likely to produce a genuine surprise.
China's pharmaceutical evolution mirrors its semiconductor and EV trajectories — years of imitation, then acceleration, then a moment when the domestic capabilities become globally competitive. That moment in pharma is arriving faster than most Western observers expect. Domestic demand is enormous. Government support is sustained. AI adoption is aggressive. And the talent pipeline from Chinese universities is deepening every year.
WuXi does not make drugs. It makes drug discovery possible. Every major Western pharmaceutical company uses WuXi's contract research and manufacturing platforms. AI-integrated discovery combined with Chinese manufacturing scale creates a cost and speed advantage that is difficult for any competitor to replicate. WuXi is to pharma what TSMC is to semiconductors — the essential platform beneath everyone else's ambition.
Hansoh is China's most serious oncology innovator. Their CNS and metabolic disease pipelines are advancing with AI-driven drug repurposing — finding new uses for existing compounds at a fraction of the discovery cost. The domestic market alone justifies the pipeline investment. Global licensing partnerships are the upside scenario.
Zai Lab's model is elegant — license innovative therapies from Western and Japanese companies, bring them to China, build the clinical and regulatory relationships, and develop internal capabilities along the way. Their oncology portfolio is strong. The AI platform partnerships accelerate local development timelines. As China's regulatory environment modernises, Zai Lab's position becomes more valuable.
The pharmaceutical industry will contribute more to global economic output between now and 2040 than at any point in history. Not because healthcare costs are rising — though they are. But because effective medicine expands human economic participation. Every Alzheimer's patient kept independent for two more years. Every cancer patient returned to work. Every rare disease child who reaches adulthood. These are not just medical outcomes. They are economic ones.
The $1Q thesis identifies Longer Lifespans as Force 12 of 16. Medicine is the primary driver of that force. And the three convergences we have described — AI acceleration, genetic medicine, demographic demand — are the mechanisms through which Force 12 compounds into the quadrillion economy.
The companies to watch are not the ones with the highest market caps today. They are the ones embedding AI most deeply, pivoting to genetic modalities earliest, and positioned in the markets where demographic demand is largest. That set includes names from Veldhoven and San Francisco — and increasingly from Mumbai, Hyderabad, and Shanghai.
The trillion-dollar pharmaceutical company is not a fantasy. Eli Lilly is already there. The next ones are being built in laboratories right now, with AI assistants identifying molecules that human chemists would have missed, and genetic scissors cutting out diseases that previous generations simply endured.
Part of an ongoing journal — observations recorded when something in the world economy is worth saying. No schedule. No noise. The next entry when there is something worth adding. Not investment advice.